Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Syndax Pharmaceuticals Inc shares valued at $304,170 were sold by Podlesak Dennis on Aug 18 ’25. At $15.84 per share, Podlesak Dennis sold 19,200 shares. The insider’s holdings dropped to 191,763 shares worth approximately $3.1 million following the completion of this transaction.
Also, Podlesak Dennis sold 19,200 shares, netting a total of over 298,408 in proceeds. Following the sale of shares at $15.54 each, the insider now holds 191,763 shares.
Before that, Podlesak Dennis had sold 19,200 shares from its account. In a trade valued at $272,521, the Director traded Syndax Pharmaceuticals Inc shares for $14.19 each. Upon closing the transaction, the insider’s holdings decreased to 19,200 shares, worth approximately $3.1 million.
Analysts at BTIG Research resumed the stock at ‘”a Buy”‘ outlook in a report released in early August. As of July 10, 2025, Goldman has initiated its “Buy” rating for SNDX. Earlier on October 24, 2024, UBS initiated its rating. Their recommendation was “a Buy” for SNDX stock.
Analyzing SNDX Stock Performance
On last trading session, Syndax Pharmaceuticals Inc [NASDAQ: SNDX] rose 0.37% to $16.19. The stock’s lowest price that day was $15.83, but it reached a high of $16.47 in the same session. During the last five days, there has been a drop of approximately -0.43%. Over the course of the year, Syndax Pharmaceuticals Inc shares have dropped approximately -21.22%. Shares of the company reached a 52-week high of $17.24 on 08/28/25 and a 52-week low of $8.58 on 05/15/25.
Support And Resistance Levels for Syndax Pharmaceuticals Inc (SNDX)
According to the 24-hour chart, there is a support level at 15.86, which, if violated, would cause prices to drop to 15.52. In the upper region, resistance lies at 16.50. The next price resistance is at 16.81. RSI (Relative Strength Index) is 72.62 on the 14-day chart, showing overbought technical sentiment.
Is Syndax Pharmaceuticals Inc subject to short interest?
Stocks of Syndax Pharmaceuticals Inc saw a sharp steep in short interest on 2025-08-15 dropping by -3.09 million shares to 20.61 million. Data from Yahoo Finance shows that the short interest on 2025-07-15 was 23.69 million shares. A decline of -14.97% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 7.76 of the overall float, the days-to-cover ratio (short ratio) decline to 7.76.
Which companies own the most shares of Syndax Pharmaceuticals Inc (SNDX)?
In terms of Syndax Pharmaceuticals Inc share price expectations, FactSet research, analysts set an average price target of 26.5 in the next 12 months, up nearly 64.29% from the previous closing price of $16.13. Analysts anticipate Syndax Pharmaceuticals Inc stock to reach 35 by 2025, with the lowest price target being 18. In spite of this, 4 analysts ranked Syndax Pharmaceuticals Inc stock as Buy at the end of 2025. On June 28, 2024, Jefferies assigned a price target of “a Buy” to the stock and initiated coverage with a $37.
